British-based pharmaceutical company AstraZeneca says it is eliminating about 700 jobs in its U.S. commercial business, including about 120 at its North American headquarters in Wilmington.
The company said Thursday that the cuts also affect sales and non-sales positions across the United States, and include roughly 80 vacant positions.
The job cuts will leave AstraZeneca with about 1,500 employees in Delaware.
AstraZeneca, which once employed close to 5,000 workers in Delaware, announced in 2013 that it was cutting 1,200 jobs at its Wilmington headquarters.
In persuading AstraZeneca to select Wilmington over Pennsylvania as the site of its U.S. headquarters in 1999, then-Gov. Tom Carper offered the company about $50 million in state incentives, including 86 acres of state-owned land and tens of millions of dollars in tax credits.
Filed Under: Drug Discovery
